4 Analysts Have This to Say About Molina Healthcare
Analysts have provided the following ratings for Molina Healthcare (NYSE:MOH) within the last quarter:
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours.
Earnings Scheduled For April 27, 2022
Companies Reporting Before The Bell
• Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter.
House Passes Bill To Cap Out-of-Pocket Insulin Costs To No More Than $35/Month
The House of Representatives voted to approve legislation that would limit cost-sharing for insulin under private health insurance and Medicare.
Analyst Ratings For Molina Healthcare
Within the last quarter, Molina Healthcare (NYSE:MOH) has observed the following analyst ratings:
BMO Capital Maintains Outperform on Molina Healthcare, Raises Price Target to $380
BMO Capital analyst Matt Borsch maintains Molina Healthcare (NYSE:MOH) with a Outperform and raises the price target from $365 to $380.
Mizuho Maintains Buy on Molina Healthcare, Raises Price Target to $345
Mizuho analyst Ann Hynes maintains Molina Healthcare (NYSE:MOH) with a Buy and raises the price target from $330 to $345.
Earnings Scheduled For February 9, 2022
Companies Reporting Before The Bell
• Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion.
